Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following ...

Atopic dermatitis (AD) is a chronic disease that affects an increasing number of children and adults. The skin is dry and ...

Sanofi has said it will press ahead with regulatory filings for atopic dermatitis (AD) candidate amlitelimab after reporting ...

Amlitelimab, an OX40 ligand–targeting therapy that modulates T-cell-mediated inflammation without causing cell depletion, ...

Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being ...

Amlitelimab is an investigational anti-OX40 ligand monoclonal antibody designed to normalize the overactive immune response in patients with atopic dermatitis.

Children who have multiple food allergies (FAs) and allergies to milk and eggs are more likely to have early-onset atopic dermatitis (AD).

Sanofi has announced that its amlitelimab has shown positive results in the treatment of patients 12 years and older with atopic dermatitis (AD).

Sanofi's amlitelimab confirms its potential in atopic dermatitis: Paris Saturday, January 24, 2026, 10:00 Hrs [IST] Following the positive COAST 1 (clinical study identifier: NCT0 ...

Citing the “totality of data,” Sanofi SA plans to file global regulatory submissions this year for amlitelimab in atopic ...

In this video interview, Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at the Northwestern ...

A Bayesian network meta-analysis comparing four oral JAK inhibitors-upadacitinib, abrocitinib, baricitinib, and ivarmacitinib ...